ARCHIVES

mTOR Inhibitor Improves PFS In Metastatic Sarcoma Patients

This article is from The Cancer Letter archive.

Vol. 34 No. 2 | February 25, 2011

Download PDF Visit The Full Archive

Related Articles

In This Issue: Congressional Testimony On NIH, NCI Appropriations, FDA Reform

May 9, 1997

Reviewers Report Progress In New Drug Prescreen System Development, Commend DTP

December 15, 1989

Policy Of 5,000 Grants Meant As Floor, Not Ceiling, Former White House Advisor Insists

March 8, 1985

FDA Approives Lilly’s Alimta For 1st-Line Metastatic NSCLC

September 26, 2008

MET Inhibitor Improved Time To Progression by 56 Percent

June 29, 2012

Cancer, AIDS Drug Screening Contracts Ok’d For Recompetition

February 28, 1992